Cargando…

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

PURPOSE: This study reports the safety, tolerability, MTD, recommended phase II dose (RP2D), pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of ceralasertib combined with carboplatin in patients with advanced solid tumors. It also examined exploratory predictive and pharm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yap, Timothy A., Krebs, Matthew G., Postel-Vinay, Sophie, El-Khouiery, Anthony, Soria, Jean-Charles, Lopez, Juanita, Berges, Alienor, Cheung, S.Y. Amy, Irurzun-Arana, Itziar, Goldwin, Andrew, Felicetti, Brunella, Jones, Gemma N., Lau, Alan, Frewer, Paul, Pierce, Andrew J., Clack, Glen, Stephens, Christine, Smith, Simon A., Dean, Emma, Hollingsworth, Simon J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Clinical Trials: Targeted Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401487/ https://www.ncbi.nlm.nih.gov/pubmed/34301752 http://dx.doi.org/10.1158/1078-0432.CCR-21-1032

Ejemplares similares

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
por: Kim, Seung Tae, et al.
Publicado: (2021)

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
por: Kwon, Minsuk, et al.
Publicado: (2022)

Dose-Dependent Bioavailability and Tissue Distribution of the ATR Inhibitor AZD6738 (ceralasertib) in Mice
por: Kiesel, Brian F., et al.
Publicado: (2022)

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
por: Wilson, Zena, et al.
Publicado: (2022)

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
por: Ring, Alistair, et al.
Publicado: (2023)

The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma
por: Talebpoor, Maryam, et al.
Publicado: (2022)

Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2015)

The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy
por: Vendetti, Frank P., et al.
Publicado: (2023)

Corrigendum: Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2016)

ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration
por: Fròsina, Guido, et al.
Publicado: (2018)

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
por: Hur, Jin, et al.
Publicado: (2021)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting repair of DNA damage
por: Suzuki, Takuya, et al.
Publicado: (2022)

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
por: Sheng, Hailong, et al.
Publicado: (2020)

AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells
por: Harata, Shinnosuke, et al.
Publicado: (2023)

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo
por: Vendetti, Frank P., et al.
Publicado: (2015)

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
por: Dillon, M.T., et al.
Publicado: (2018)

Indirect Decompression Failure After Lateral Lumbar Interbody Fusion—Reported Failures and Predictive Factors: Systematic Review
por: Kirnaz, Sertac, et al.
Publicado: (2020)

Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells
por: Isono, Makoto, et al.
Publicado: (2022)

AZD6738 Inhibits fibrotic response of conjunctival fibroblasts by regulating checkpoint kinase 1/P53 and PI3K/AKT pathways
por: Huang, Longxiang, et al.
Publicado: (2022)

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
por: Choudhury, Atish D., et al.
Publicado: (2022)

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
por: Roschewski, Mark, et al.
Publicado: (2023)

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
por: Lim, Emerson A., et al.
Publicado: (2022)

Mind Perception Is the Essence of Morality
por: Gray, Kurt, et al.
Publicado: (2012)

Neuroethics: A New Way of Doing Ethics
por: Levy, Neil
Publicado: (2011)

A Life Worth Giving? The Threshold for Permissible Withdrawal of Life Support From Disabled Newborn Infants
por: Wilkinson, Dominic James
Publicado: (2011)

Just How Cognitive Is “Cognitive Enhancement”? On the Significance of Emotions in University Students' Experiences with Study Drugs
por: Vrecko, Scott
Publicado: (2013)

Troubled sleep: Night waking, breastfeeding and parent–offspring conflict
por: Haig, David
Publicado: (2014)

Thinking Ahead on Deep Brain Stimulation: An Analysis of the Ethical Implications of a Developing Technology
por: Johansson, Veronica, et al.
Publicado: (2014)

Brave New Love: The Threat of High-Tech “Conversion” Therapy and the Bio-Oppression of Sexual Minorities
por: Earp, Brian D., et al.
Publicado: (2014)

Patient and Citizen Participation in Health: The Need for Improved Ethical Support
por: Williamson, Laura
Publicado: (2014)

Ethics of Clinical Science in a Public Health Emergency: Drug Discovery at the Bedside
por: Edwards, Sarah J. L.
Publicado: (2013)

Treating Patients as Persons: A Capabilities Approach to Support Delivery of Person-Centered Care
por: Entwistle, Vikki A., et al.
Publicado: (2013)

The Use of Deception in Public Health Behavioral Intervention Trials: A Case Study of Three Online Alcohol Trials
por: McCambridge, Jim, et al.
Publicado: (2013)

If I Could Just Stop Loving You: Anti-Love Biotechnology and the Ethics of a Chemical Breakup
por: Earp, Brian D., et al.
Publicado: (2013)

A Threat to Autonomy? The Intrusion of Predictive Brain Implants
por: Gilbert, Frederic
Publicado: (2015)

A prospective study of macrophage migration inhibitory factor as a marker of inflammatory detection
por: Zhang, Chao, et al.
Publicado: (2009)

Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework
por: Evitt, Niklaus H., et al.
Publicado: (2015)

Developmental plasticity: Bridging research in evolution and human health
por: Lea, Amanda J, et al.
Publicado: (2018)

The ER membrane protein complex is a transmembrane domain insertase
por: Guna, Alina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hmoo3vvkfakebocdpng0547kv7